Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MRG003 |
| Synonyms | |
| Therapy Description |
MRG003 is an antibody-drug conjugate (ADC) targeting EGFR, which potentially decreases tumor growth (J Clin Oncol 42, 2024 (suppl 16; abstr 6013)). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MRG003 | MRG-003|MRG 003 | EGFR Antibody 75 | MRG003 is an antibody-drug conjugate (ADC) targeting EGFR, which potentially decreases tumor growth (J Clin Oncol 42, 2024 (suppl 16; abstr 6013)). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06959108 | Phase II | MRG003 HX008 + MRG003 | Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck (IDEAL) | Recruiting | FRA | 0 |